Supplementary Tables 3 - 6 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

PDF file, 79K, Supplementary Table 3 - Mouse body weights for data in Figure 4A Body Weights expressed as a percentage of the weight on day 0 for mice bearing HT29 xenografts and treated with gemcitabine (100mg/kg iv), CCT244747 (75mg/kg po) or the combination. Values are mean�SE, n= 3 to 6. Supplementary Table 4 - Mouse body weights for data in Figure 4C Body Weights expressed as a percentage of the weight on day 0 for mice bearing HT29 xenografts and treated with irinotecan (25mg/kg ip), CCT244747 (150mg/kg po) or the combination. Values are mean�SE, n= 3 to 6. Supplementary Table 5 - Mouse body weights for data in Figure 4D Body Weights expressed as a percentage of the weight on day 0 for mice bearing Calu6 xenografts and treated with gemcitabine (100 mg/kg iv), CCT244747 (75mg/kg po) or the combination. Values are mean�SE, n= 3 to 6. Supplementary Table 6 - Mouse body weights for data in Supplementary Table 2 Body Weights expressed as a percentage of the weight on day 0 for mice bearing SW620 xenografts and treated with gemcitabine (100 mg/kg iv), CCT244747 (75mg/kg po) or the combination. Values are mean�SE, n= 3 to 6.